How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,375 results for

Cushing Response

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. High-resolution<sup>18</sup>F-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for pituitary adenoma detection in Cushing disease. Full Text available with Trip Pro

High-resolution18F-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for pituitary adenoma detection in Cushing disease. OBJECT High-resolution PET (hrPET) performed using a high-resolution research tomograph is reported as having a resolution of 2 mm and could be used to detect corticotroph adenomas through uptake of(18)F-fluorodeoxyglucose ((18)F-FDG). To determine the sensitivity of this imaging modality, the authors compared(18)F-FDG hrPET and MRI (...) detection of pituitary adenomas in Cushing disease (CD). METHODS Consecutive patients with CD who underwent preoperative(18)F-FDG hrPET and MRI (spin echo [SE] and spoiled gradient recalled [SPGR] sequences) were prospectively analyzed. Standardized uptake values (SUVs) were calculated from hrPET and were compared with MRI findings. Imaging findings were correlated to operative and histological findings. RESULTS Ten patients (7 females and 3 males) were included (mean age 30.8 ± 19.3 years; range 11-59

2014 Journal of Neurosurgery

102. Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome

of Metyrapone in Patients With Endogenous Cushing's Syndrome (PROMPT) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02297945 Recruitment Status : Unknown Verified February 2017 by HRA Pharma. Recruitment status was: Recruiting First Posted : November 21, 2014 Last Update Posted : February 15, 2017 Sponsor (...) : HRA Pharma Information provided by (Responsible Party): HRA Pharma Study Details Study Description Go to Brief Summary: The purpose of this prospective, international phase III/IV study is to assess the efficacy and safety of metyrapone in patients with endogenous Cushing's syndrome during up to 36 weeks of treatment. The ability of metyrapone (250 mg capsules) to normalize urinary free cortisol (UFC) levels will be assessed during up to 36 weeks (9 months) of treatment. Condition or disease

2014 Clinical Trials

103. Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease

adding more. Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02310269 Recruitment Status : Recruiting First Posted : December 8, 2014 (...) Last Update Posted : August 20, 2018 See Sponsor: Novartis Pharmaceuticals Information provided by (Responsible Party): Novartis ( Novartis Pharmaceuticals ) Study Details Study Description Go to Brief Summary: This is a non-interventional, multinational, multi-center post-marketing study, to further document the safety and efficacy of pasireotide s.c. administered in routine clinical practice in patients with Cushing's disease. Patients with Cushing's disease and treated with pasireotide s.c

2014 Clinical Trials

104. Cushing Syndrome (Overview)

activation, [ ] changes in the enzyme adenosine monophosphate-activated protein kinase activity, [ ] and modulation of activator protein 1 (Fos/Jun) [ ] are some of the important pathways that have been described. More research still needs to be conducted to fully understand the underlying signaling pathways and glucocorticoid tissue-specific responses. A study by Serfling et al suggested that weight gain in iatrogenic Cushing syndrome may be related to a glucocorticoid-stimulated rise in the amygdala (...) Cushing Syndrome (Overview) Iatrogenic Cushing Syndrome: Background, Frequency, Mortality/Morbidity Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTE3MzY1LW92ZXJ2aWV3 processing > Iatrogenic Cushing Syndrome

2014 eMedicine.com

105. Pseudo-Cushing Syndrome (Diagnosis)

. . Bernini GP, Argenio GF, Cerri F, Franchi F. Comparison between the suppressive effects of dexamethasone and loperamide on cortisol and ACTH secretion in some pathological conditions. J Endocrinol Invest . 1994 Nov. 17 (10):799-804. . Malerbi DA, Fragoso MC, Vieira Filho AH, Brenlha EM, Mendonça BB. Cortisol and adrenocorticotropin response to desmopressin in women with Cushing's disease compared with depressive illness. J Clin Endocrinol Metab . 1996 Jun. 81 (6):2233-7. . Tirabassi G, Papa R, Faloia E (...) Pseudo-Cushing Syndrome (Diagnosis) Pseudo-Cushing Syndrome: Overview, Causes and Complications, History and Physical Examination Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTI0NzE4LW92ZXJ2aWV3 processing

2014 eMedicine.com

106. Pseudo-Cushing Syndrome (Follow-up)

. . Bernini GP, Argenio GF, Cerri F, Franchi F. Comparison between the suppressive effects of dexamethasone and loperamide on cortisol and ACTH secretion in some pathological conditions. J Endocrinol Invest . 1994 Nov. 17 (10):799-804. . Malerbi DA, Fragoso MC, Vieira Filho AH, Brenlha EM, Mendonça BB. Cortisol and adrenocorticotropin response to desmopressin in women with Cushing's disease compared with depressive illness. J Clin Endocrinol Metab . 1996 Jun. 81 (6):2233-7. . Tirabassi G, Papa R, Faloia E (...) Pseudo-Cushing Syndrome (Follow-up) Pseudo-Cushing Syndrome: Overview, Causes and Complications, History and Physical Examination Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTI0NzE4LW92ZXJ2aWV3 processing

2014 eMedicine.com

107. Pseudo-Cushing Syndrome (Treatment)

. . Bernini GP, Argenio GF, Cerri F, Franchi F. Comparison between the suppressive effects of dexamethasone and loperamide on cortisol and ACTH secretion in some pathological conditions. J Endocrinol Invest . 1994 Nov. 17 (10):799-804. . Malerbi DA, Fragoso MC, Vieira Filho AH, Brenlha EM, Mendonça BB. Cortisol and adrenocorticotropin response to desmopressin in women with Cushing's disease compared with depressive illness. J Clin Endocrinol Metab . 1996 Jun. 81 (6):2233-7. . Tirabassi G, Papa R, Faloia E (...) Pseudo-Cushing Syndrome (Treatment) Pseudo-Cushing Syndrome: Overview, Causes and Complications, History and Physical Examination Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTI0NzE4LW92ZXJ2aWV3 processing

2014 eMedicine.com

108. Glucocorticoid Therapy and Cushing Syndrome (Overview)

Glucocorticoid Therapy and Cushing Syndrome (Overview) Glucocorticoid Therapy and Cushing Syndrome: Background, Pathophysiology, Endogenous Cushing syndrome Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvOTIxMDg2LW92ZXJ2aWV3 processing > Glucocorticoid Therapy and Cushing Syndrome Updated: Dec 11, 2015 Author: George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London); Chief Editor: Sasigarn A Bowden, MD Share Email Print Feedback Close Sections Sections Glucocorticoid Therapy and Cushing Syndrome Overview Background Cushing syndrome (CS) takes its name from Harvey Cushing, who, in 1912, was one of the first physicians to report a patient affected with excessive glucocorticoid. [ ] More than 99% of cases of Cushing

2014 eMedicine Pediatrics

109. Glucocorticoid Therapy and Cushing Syndrome (Treatment)

Glucocorticoid Therapy and Cushing Syndrome (Treatment) Glucocorticoid Therapy and Cushing Syndrome Treatment & Management: Medical Care, Surgical Care, Consultations Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvOTIxMDg2LXRyZWF0bWVudA== processing > Glucocorticoid Therapy and Cushing Syndrome Treatment & Management Updated: Dec 11, 2015 Author: George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London); Chief Editor: Sasigarn A Bowden, MD Share Email Print Feedback Close Sections Sections Glucocorticoid Therapy and Cushing Syndrome Treatment Medical Care Treatment of Cushing syndrome involves identifying the underlying cause, whereas management of exogenous hypercortisolism involves optimization of glucocorticoid dose and route

2014 eMedicine Pediatrics

110. Glucocorticoid Therapy and Cushing Syndrome (Follow-up)

Glucocorticoid Therapy and Cushing Syndrome (Follow-up) Glucocorticoid Therapy and Cushing Syndrome Follow-up: Further Outpatient Care, Inpatient & Outpatient Medications, Transfer Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvOTIxMDg2LWZvbGxvd3Vw processing > Glucocorticoid Therapy and Cushing Syndrome Follow-up Updated: Dec 11, 2015 Author: George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London); Chief Editor: Sasigarn A Bowden, MD Share Email Print Feedback Close Sections Sections Glucocorticoid Therapy and Cushing Syndrome Follow-up Further Outpatient Care Regular follow-up care is required for patients with Cushing syndrome (CS) who are receiving adrenal steroid replacement. Obtain a history of the number of illnesses, frequency

2014 eMedicine Pediatrics

111. Cushing Syndrome (Diagnosis)

activation, [ ] changes in the enzyme adenosine monophosphate-activated protein kinase activity, [ ] and modulation of activator protein 1 (Fos/Jun) [ ] are some of the important pathways that have been described. More research still needs to be conducted to fully understand the underlying signaling pathways and glucocorticoid tissue-specific responses. A study by Serfling et al suggested that weight gain in iatrogenic Cushing syndrome may be related to a glucocorticoid-stimulated rise in the amygdala (...) Cushing Syndrome (Diagnosis) Iatrogenic Cushing Syndrome: Background, Frequency, Mortality/Morbidity Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTE3MzY1LW92ZXJ2aWV3 processing > Iatrogenic Cushing Syndrome

2014 eMedicine.com

112. Pseudo-Cushing Syndrome (Overview)

. . Bernini GP, Argenio GF, Cerri F, Franchi F. Comparison between the suppressive effects of dexamethasone and loperamide on cortisol and ACTH secretion in some pathological conditions. J Endocrinol Invest . 1994 Nov. 17 (10):799-804. . Malerbi DA, Fragoso MC, Vieira Filho AH, Brenlha EM, Mendonça BB. Cortisol and adrenocorticotropin response to desmopressin in women with Cushing's disease compared with depressive illness. J Clin Endocrinol Metab . 1996 Jun. 81 (6):2233-7. . Tirabassi G, Papa R, Faloia E (...) Pseudo-Cushing Syndrome (Overview) Pseudo-Cushing Syndrome: Overview, Causes and Complications, History and Physical Examination Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTI0NzE4LW92ZXJ2aWV3 processing

2014 eMedicine.com

113. Glucocorticoid Therapy and Cushing Syndrome (Diagnosis)

Glucocorticoid Therapy and Cushing Syndrome (Diagnosis) Glucocorticoid Therapy and Cushing Syndrome: Background, Pathophysiology, Endogenous Cushing syndrome Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvOTIxMDg2LW92ZXJ2aWV3 processing > Glucocorticoid Therapy and Cushing Syndrome Updated: Dec 11, 2015 Author: George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London); Chief Editor: Sasigarn A Bowden, MD Share Email Print Feedback Close Sections Sections Glucocorticoid Therapy and Cushing Syndrome Overview Background Cushing syndrome (CS) takes its name from Harvey Cushing, who, in 1912, was one of the first physicians to report a patient affected with excessive glucocorticoid. [ ] More than 99% of cases of Cushing

2014 eMedicine Pediatrics

114. Maintenance of Response After rTMS for Depression Using tDCS

Maintenance of Response After rTMS for Depression Using tDCS Maintenance of Response After rTMS for Depression Using tDCS - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Maintenance of Response After rTMS (...) for Depression Using tDCS (START) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03708159 Recruitment Status : Recruiting First Posted : October 17, 2018 Last Update Posted : October 17, 2018 See Sponsor: Centre for Addiction

2018 Clinical Trials

115. Efficacy and Neural Mediators of Response to Trauma Management Therapy for PTSD

Efficacy and Neural Mediators of Response to Trauma Management Therapy for PTSD Efficacy and Neural Mediators of Response to Trauma Management Therapy for PTSD - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Efficacy and Neural Mediators of Response to Trauma Management Therapy for PTSD The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03449576 Recruitment Status : Enrolling by invitation First Posted : February 28, 2018 Last Update Posted : January 16, 2019 Sponsor: VA Office of Research and Development

2018 Clinical Trials

116. Androgen Responses to hCG and Ovarian Morphology in PCOS

Androgen Responses to hCG and Ovarian Morphology in PCOS Androgen Responses to hCG and Ovarian Morphology in PCOS - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Androgen Responses to hCG and Ovarian (...) Morphology in PCOS The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03489668 Recruitment Status : Recruiting First Posted : April 5, 2018 Last Update Posted : August 9, 2018 See Sponsor: Poznan University of Medical Sciences

2018 Clinical Trials

117. Diagnostic accuracy and comparison of BIPSS in response to lysine vasopressin and hCRH Full Text available with Trip Pro

Diagnostic accuracy and comparison of BIPSS in response to lysine vasopressin and hCRH Bilateral inferior petrosal sinus sampling (BIPSS) using hCRH is currently considered the 'gold standard' test for the differential diagnosis of ACTH-dependent Cushing's syndrome (CS). Vasopressin is more potent than CRH to stimulate ACTH secretion as shown in animal studies; however, no comparative data of its use are available during BIPSS.To study the diagnostic accuracy and comparison of hCRH and lysine (...) vasopressin (LVP) stimulation during BIPSS.29 patients (27-Cushing's disease, 2-ectopic CS; confirmed on histopathology) underwent BIPSS and were included for the study. Patients were randomized to receive hCRH, 5 U LVP or 10 U LVP during BIPSS for ACTH stimulation. BIPSS and contrast-enhanced magnetic resonance imaging (CEMRI) were compared with intra-operative findings of trans-sphenoidal surgery (TSS) for localization and lateralization of the ACTH source.BIPSS correctly localized the source of ACTH

2018 Endocrine connections Controlled trial quality: uncertain

118. Differences in adiposity in Cushing syndrome caused by PRKAR1A mutations: clues for the role of cyclic AMP signaling in obesity and diagnostic implications. Full Text available with Trip Pro

Differences in adiposity in Cushing syndrome caused by PRKAR1A mutations: clues for the role of cyclic AMP signaling in obesity and diagnostic implications. The cAMP signaling pathway is implicated in bilateral adrenocortical hyperplasias. Bilateral adrenocortical hyperplasia is often associated with ACTH-independent Cushing syndrome (CS) and may be caused by mutations in genes such as PRKAR1A, which is responsible for primary pigmented nodular adrenocortical disease (PPNAD). PRKAR1A regulates (...) ) and without (n = 32) PRKAR1A mutations and a comparison group with aldosterone-producing adenomas (APAs) (n = 6). In addition, clinical data from a larger group of patients with Cushing disease (n = 89) and hyperaldosteronism (n = 26) were used for comparison.Body mass index (BMI), abdominal computed tomography scans, and cortisol data were collected preoperatively. PAT was assayed for PKA activity, cAMP levels, and PKA subunit expression.BMI was lower in adult patients with CS with PRKAR1A mutations

2013 Journal of Clinical Endocrinology and Metabolism

119. The role of Harvey Cushing and Walter Dandy in the evolution of modern neurosurgery in the Netherlands, illustrated by their correspondence. Full Text available with Trip Pro

Medical Archives in Baltimore) of Cushing and Dandy with their Dutch disciples. The correspondence provides a unique inside view into the minds of both neurosurgical giants. After the neurologist Bernard Brouwer had paved the way for sending the Dutch surgeon Ignaz Oljenick overseas, Cushing personally took the responsibility to train him (1927-1929). On his return to Amsterdam, Oljenick and Brouwer established the first neurosurgical department in the country. Encouraged by Oljenick's favorable (...) The role of Harvey Cushing and Walter Dandy in the evolution of modern neurosurgery in the Netherlands, illustrated by their correspondence. The development of modern neurosurgery in the Netherlands, which took place in the 1920s, was highly influenced by the personal involvement of both Harvey Cushing and Walter Dandy, each in his own way. For the present article, the authors consulted the correspondence (kept at the Cushing/Whitney Medical Library in New Haven and the Alan Mason Chesney

2013 Journal of Neurosurgery

120. Predictors of Mortality and Long-term Outcomes in Treated Cushing's Disease: A Study of 346 Patients. Full Text available with Trip Pro

Predictors of Mortality and Long-term Outcomes in Treated Cushing's Disease: A Study of 346 Patients. Active Cushing's disease (CD) confers a 4-fold increase in mortality and is associated with significant morbidities. Although excess mortality risk may persist even after CD treatment, predictors of risk in treated CD are not well understood.To identify predictors of mortality, cardiovascular (CV) disease, and recurrence after long-term follow-up among patients with treated CD.A retrospective (...) chart review was conducted to evaluate patients with CD who underwent transsphenoidal adenectomy with a single surgeon.Patients were categorized based on disease response after initial treatment. Cox proportional hazard models identified predictors of mortality, recurrence, and CV outcomes in the overall cohort and each subgroup.Three hundred forty-six subjects were included. Mean age was 39.9 years, and mean duration of follow-up was 6.3 years (range, 1 mo to 30 y). Duration of exposure to excess

2013 Journal of Clinical Endocrinology and Metabolism

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>